Overview

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

Status:
Withdrawn
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label multicenter, study to assess the pharmacokinetic interaction of rifampin with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Collaborator:
Genentech, Inc.
Treatments:
Rifampin
Venetoclax